非人灵长类免疫原性模型中第三剂加强接种后的泛SARS中和反应
该研究在非人灵长类动物中评估了单价和二价mRNA疫苗作为基础免疫或加强免疫的效果。研究发现,以mRNA疫苗加强免疫预免疫动物后,中和抗体滴度大幅升高,对包括SARS-CoV-1在内的所有测试变异株的广度扩展,且该广度与疫苗序列或形式无关。数据支持第三剂疫苗接种是提升现有滴度并改善抗体广度的关键。
要点
- 在未免疫非人灵长类中,单价或二价mRNA疫苗仅产生对异源变异株的 modest 中和滴度。
- 对预免疫非人灵长类加强接种mRNA疫苗后,中和滴度大幅升高,广度扩展至所有测试变异株及SARS-CoV-1。
- 中和反应广度与疫苗序列或形式无关,MRT5500或重组亚单位Spike蛋白(含佐剂)均可作为加强针诱导广谱中和抗体。
核心结论
- 数据支持第三剂疫苗接种是提升现有滴度并改善抗体广度以应对关切变异株(包括RBD E484K突变的Beta、Gamma)的关键。
研究设计与样本
- 在非人灵长类动物中评估单价和二价mRNA疫苗作为基础免疫或加强免疫的免疫原性研究。
主要发现
- 在未免疫非人灵长类中,基于D614的MRT5500和基于Beta的MRT5500β以序贯方案或二价组合测试,对异源变异株产生modest中和滴度。
- 对预免疫非人灵长类加强接种mRNA疫苗后,观察到中和滴度大幅升高,广度扩展至所有测试变异株,并显著涵盖SARS-CoV-1。
- 中和反应广度与疫苗序列或形式无关,MRT5500或重组亚单位Spike蛋白(含佐剂)作为加强针均可在MRT5500基础免疫的非人灵长类中诱导广谱中和抗体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of SARS-CoV-2 variants, especially Beta and Delta, has raised concerns about the reduced protection from previous infection or vaccination based on the original Wuhan-Hu-1 (D614) virus. To identify promising regimens for inducing neutralizing titers towards new variants, we evaluated monovalent and bivalent mRNA vaccines either as primary vaccination or as a booster in nonhuman primates (NHPs). Two mRNA vaccines, D614-based MRT5500 and Beta-based MRT5500β, tested in sequential regimens or as a bivalent combination in naïve NHPs produced modest neutralizing titers to heterologous variants. However, when mRNA vaccines were administered as a booster to pre-immune NHPs, we observed a robust increase in neutralizing titers with expanded breadth towards all tested variants, and notably SARS-CoV-1. The breadth of the neutralizing response was independent of vaccine sequence or modality, as we further showed either MRT5500 or recombinant subunit Spike protein (with adjuvant) can serve as boosters to induce broadly neutralizing antibodies in the NHPs primed with MRT5500. The data support the notion that a third vaccination is key to boosting existing titers and improving the breadth of antibodies to address variants of concern, including those with an E484K mutation in the Receptor Binding Domain (RBD) (Beta, Gamma).
引用
- Kalnin KV, Plitnik T, Kishko M, et al. Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. Vaccine. 2022. PMID: 35101265. doi:10.1016/j.vaccine.2022.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。